The drugs would still not be FDA-approved, and the FDA would still not vouch for their safety or effectiveness. Koehl Robinson, founder and CEO of CeliaRX, a telehealth company that sells injectable and topical peptides compounded by a 503A pharmacy partner (not the ones on the FDAs potential unbanned list), says that if the peptides are reclassified, it would likely open up new possibilities for her customers, as well as lead to more clarity and less confusion
What Is BPC-157 and How Does It Support Healing
The clinical consequences could range from local inflammation or rash through to serious health issues, such as systemic hypersensitivity, including anaphylaxis, or antibody formation
Category 1 Bulk substance the FDA considers eligible for use in compounding pending final rulemaking Generally permitted Category 2 Bulk substance the FDA has significant safety, identity, or quality concerns about Not permitted during review Category 3 Substance requiring further evaluation Case-by-case Critically, Category 1 status is not FDA approval